| Characteristic | Patients, n = 379 (%) | 5-Year OS* (%) | pa | 10-Year OS* (%) | pa | 5-Year EFS† (%) | pa | 10-Year EFS† (%) | pa |
| |
|
| <0.001 |
| 0.012 |
| <0.001 |
| 0.081 |
| <20 years | 60 (15.8) | 43 (71.7) |
| 19 (31.7) |
| 41 (68.3) |
| 18 (30.0) |
|
| 20 - 40 Years | 290 (76.5) | 196 (67.6) |
| 122 (42.1) |
| 173 (59.7) |
| 113 (39.0) |
|
| ≥40 Years | 29 (7.7) | 17 (58.6) |
| 8 (27.6) |
| 14 (48.2) |
| 7 (24.1) |
|
| |
|
| 0.792 |
| 0.236 |
| 0.569 |
| 0.225 |
| Male | 220 (58.0) | 144 (65.5) |
| 80 (36.4) |
| 128 (58.2) |
| 74 (33.6) |
|
| Female | 159 (42.0) | 107 (67.3) |
| 69 (43.4) |
| 98 (61.6) |
| 74 (40.3) |
|
| |
|
| 0.003 |
| 0.542 |
| 0.003 |
| 0.240 |
| Extremity | 343 (90.5) | 237 (69.1) |
| 139 (40.4) |
| 214 (62.5) |
| 129 (37.5) |
|
| Pelvis | 24 (6.3) | 9 (37.5) |
| 7 (29.2) |
| 7 (29.2) |
| 5 (20.8) |
|
| Etc | 12 (3.2) | 6 (50.0) |
| 5 (41.7) |
| 5 (41.7) |
| 5 (41.7) |
|
| |
|
| <0.001 |
| <0.001 |
| <0.001 |
| <0.001 |
| Localized (meta(−)) | 272 (71.8) | 209 (76.8) |
| 129 (47.4) |
| 209 (76.8) |
| 129 (47.4) |
|
| Metastasis (+) | 107 (28.2) | 19 (17.8) |
| 16 (15.1) |
| 15 (14.9) |
| 8 (7.5) |
|
| |
|
| 0.577 |
| <0.001 |
| 0.498 |
| 0.024 |
| OB‡ | 243 (65.4) | 167 (68.5) |
| 102 (41.9) |
| 152 (62.5) |
| 97 (39.9) |
|
| FB§ | 54 (14.2) | 32 (59.3) |
| 10 (18.5) |
| 29 (53.7) |
| 9 (16.7) |
|
| CB∥ | 21 (5.5) | 15 (71.4) |
| 14 (61.9) |
| 10 (47.6) |
| 9 (42.9) |
|
| Others | 35 (9.2) | 21 (60.0) |
| 13 (37.1) |
| 19 (54.3) |
| 12 (34.3) |
|
| Unknown | 21 (5.5) | 13 (61.9) |
| 9 (42.9) |
| 13 (61.9) |
| 9 (42.9) |
|
| |
|
| <0.001 |
| <0.001 |
| 0.007 |
| <0.001 |
| Good Response (Necrosis ≥ 90%) | 144 (40.9) | 119 (82.6) |
| 95 (65.8) |
| 118 (81.9) |
| 94 (65.2) |
|
| Poor Response (Necrosis < 90%) | 224 (59.1) | 128 (57.1) |
| 47 (21.0) |
| 101 (45.1) |
| 37 (16.5) |
|